This is the authors' abstract. We don't add key points for this paper.
Since the coronavirus disease of 2019 (COVID-19) pandemic swept across the world, the flare of immune-mediated disease following SARS-COV-2 infection has emerged rapidly. Previous studies have documented a growing number of cases of IgA nephropathy (IgAN) subsequent to COVID-19 infection. IgAN has been established as a complement mediated autoimmune disease. Nevertheless, the characteristics of clinical and immunological features in patients with IgAN after COVID-19 infection was scantily reported and merited further exploration.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: